コンテンツへスキップ
Merck

Lactic acid oligomers (OLAs) as prodrug moieties.

Die Pharmazie (2013-03-09)
J Kruse, B Lachmann, R Lauer, S Eppacher, C R Noe
要旨

In this paper we propose the use of lactic acid oligomers (OLAs) as prodrug moieties. Two synthetic approaches are presented, on the one hand a non selective oligomerisation of lactic acid and on the other hand a block synthesis to tetramers of lactic acid. Dimers of lactic acid were investigated with respect to their plasma stability and their adsorption to albumine. Ibuprofen was chosen as the first drug for OLAylation. The ester 19 of LA(1)-ibuprofen was evaluated with respect to the degradation to human plasma and the adsorption to albumine. All results indicate that lactic acid oligomers are promising prodrug moieties.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
イブプロフェン, ≥98% (GC)
Sigma-Aldrich
(S)-(+)-イブプロフェン, ReagentPlus®, 99%
Supelco
イブプロフェン
Supelco
イブプロフェン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
イブプロフェン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
イブプロフェン ナトリウム塩, ≥98% (GC)
イブプロフェン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
イブプロフェン, meets USP testing specifications
イブプロフェン, European Pharmacopoeia (EP) Reference Standard